ArticleJournal of neuro-oncology2025
Clinical and molecular characteristics and prognostic factors of diffuse astrocytoma, IDH-wildtype, not elsewhere classified.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Utility and limitations of 18F-fluciclovine PET for biopsy targeting in a nonenhancing diffuse glioma with a gliomatosis cerebri-like growth pattern: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeThe clinical nature of IDH-wildtype astrocytoma, not elsewhere classified (NEC), is poorly understood. To this end, we aimed to investigate the clinical, molecular, imaging, and prognosis of histological grade 2 and 3 IDH-wildtype diffuse astrocytoma, NEC.
methodsRetrospective chart and imaging reviews were performed for 46 patients with IDH-wildtype diffuse astrocytoma, NEC. Data regarding clinical, histopathological, molecular markers, MRI findings, and the extent of resection were collected. Univariable and multivariable Cox analyses were performed for overall survival (OS).
resultsThe median OS was 45.0 months (95% CI 27.7–62.4). Multivariable analysis identified older age at diagnosis (hazard ratio [HR] = 1.10, P = 0.007), higher Ki-67 index (HR = 1.09, P = 0.002), and non-gross total resection (HR = 3.57, P = 0.042) as independent predictors of unfavorable OS. Tumors with genetic alterations such as amplification of KIT (P = 0.024) and PDGFRA (P = 0.034), and mutations in ATM (P = 0.050) showed an increased Ki-67 index. Tumors with higher histological grade (P < 0.001) and infiltrative appearance on MRI (P = 0.029) also showed an increased Ki-67 index. For patients with Ki-67 index ≥ 5, addition of adjuvant temozolomide therapy resulted in a survival benefit (P = 0.014).
conclusionOur findings support the importance of maximal safe resection and prognostic value of the Ki-67 index in this tumor. KIT, PDGFRA amplification and ATM mutations were associated with the increased Ki-67 indices, and targeted therapies against these alterations warrant further investigation.
Indexed as
Identifiers
41324809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.